Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer

The preoperative endocrine prognostic index (PEPI) predicts survival after neoadjuvant endocrine therapy (NAE) using aromatase inhibitors (AIs) for women with postmenopausal estrogen receptor (ER)-positive breast cancer irrespective of the human epidermal growth factor receptor 2 (HER2) status. Although the progesterone receptor (PgR) is also a prognostic factor for ER-positive breast cancer, the PgR status was not considered a prognostic factor in the original PEPI scoring system. In this study, we investigated the utility of a modified PEPI including the PgR status (PEPI-P) as a prognostic factor after NAE for postmenopausal patients with ER-positive and HER2-negative breast cancer. We enrolled 107 patients with invasive ER-positive and HER2-negative breast cancer treated with exemestane for ≥4 months as NAE. We initially assessed PEPI and compared survival between the groups. Additionally, we obtained an effective cutoff for PgR through survival analysis. Then, we assessed the survival significance of PEPI-P. A PgR staining rate of 50% was the most significant cutoff for predicting recurrence-free survival (RFS) and cancer-specific survival (CSS). PEPI was a significant prognostic factor; moreover, PEPI-P was the most significant prognostic indicator for RFS and CSS. PEPI-P is a potent prognostic indicator of survival after NAE using AIs for postmenopausal patients with ER-positive and HER2-negative breast cancer. This modified PEPI may be useful for therapeutic decision-making regarding postmenopausal ER-positive and HER2-negative breast cancer after NAE.

[1]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Kurosumi,et al.  Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index , 2017, BMC Cancer.

[4]  S. Mani,et al.  Recent advances of highly selective CDK4/6 inhibitors in breast cancer , 2017, Journal of Hematology & Oncology.

[5]  J. Olson,et al.  Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Mallon,et al.  The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone , 2016, British Journal of Cancer.

[7]  Elgene Lim,et al.  Renewed interest in the progesterone receptor in breast cancer , 2016, British Journal of Cancer.

[8]  C. Caldas,et al.  Corrigendum: Progesterone receptor modulates ERα action in breast cancer , 2015, Nature.

[9]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[11]  A. Thompson,et al.  Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.

[12]  Ben Tran,et al.  Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.

[13]  C. Lange,et al.  Progesterone receptor action: defining a role in breast cancer , 2011, Expert review of endocrinology & metabolism.

[14]  M. Kurosumi,et al.  Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? , 2011, Breast cancer.

[15]  Jigisha P. Thakkar,et al.  A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. , 2011, The oncologist.

[16]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[17]  S. Hayashi,et al.  Estrogen signaling pathway and hormonal therapy , 2008, Breast cancer.

[18]  T. Shien,et al.  Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. , 2007, Breast.

[19]  V. Semiglazov,et al.  Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer , 2007, Cancer.

[20]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[21]  A. Buzdar,et al.  Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer , 2006, Cancer.

[22]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Kornblihtt,et al.  Progestins Induce Transcriptional Activation of Signal Transducer and Activator of Transcription 3 (Stat3) via a Jak- and Src-Dependent Mechanism in Breast Cancer Cells , 2005, Molecular and Cellular Biology.

[24]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[25]  I. Smith Neoadjuvant Endocrine Therapy , 2004 .

[26]  Christopher J. Barnes,et al.  The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Molinolo,et al.  Progesterone receptors - animal models and cell signalling in breast cancer: Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer , 2002, Breast Cancer Research.

[28]  M. Ellis,et al.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Horwitz,et al.  Progesterone Regulates Transcription of the p21 WAF1 Cyclindependent Kinase Inhibitor Gene through Sp1 and CBP/p300* , 1998, The Journal of Biological Chemistry.